rezolute CEO Elam Nevan buys $34,999 in common shares

Elam Nevan, CEO and director of Rezolute , Inc. (NASDAQ:RZLT), recently acquired 12,302 common shares of the company. The purchase, which took place on March 27, 2025, was executed at a weighted average price of $2.845 per share, with the transaction amounting to a total value of $34,999. The shares were bought in multiple transactions at prices ranging from $2.83 to $2.87. According to InvestingPro data, this insider purchase comes as the stock trades near oversold levels, having declined over 40% year-to-date. Analyst price targets range from $9 to $16, suggesting significant upside potential. Following this transaction, Nevan’s direct ownership in Rezolute stands at 224,119 shares. The company maintains strong liquidity with a current ratio of 9.3, and InvestingPro analysis indicates the stock is currently undervalued. For deeper insights into insider trading patterns and comprehensive valuation metrics, explore the detailed Pro Research Report available on InvestingPro, covering over 1,400 US stocks.

In other recent news, Rezolute, Inc. has reported significant progress in its clinical trials and financial outlook. The company is advancing its Phase 3 study of ersodetug, with the Data Monitoring Committee approving the enrollment of infants into the double-blind portion of the sunRIZE study, aimed at treating congenital hyperinsulinism (HI). This development follows a positive safety assessment, allowing the company to proceed with dosing in the trial. Financially, Rezolute concluded the quarter with approximately $105 million in cash reserves, a position that analysts at JMP Securities believe will enable continued development without immediate funding concerns. As a result, JMP Securities increased their price target for Rezolute to $9.00, maintaining a Market Outperform rating. Additionally, H.C. Wainwright reiterated its Buy rating on Rezolute shares with a $14.00 price target, highlighting the company’s approval to enroll infants in the Phase 3 study as a positive indicator of ersodetug’s safety profile. The FDA had previously lifted partial clinical holds, allowing Rezolute to enroll U.S. patients over three months old, and the company plans to activate U.S. study sites soon. In a strategic move, Rezolute also expanded its board by appointing Erik Harris, a biopharma veteran, to guide the company through its clinical advancements and potential commercialization efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.